A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-β1 in the development of myelofibrosis

Blood

Volumn 105, Issue 9, 2005, Pages 3493-3501

  Vannucchi, Alessandro M ^b   Bianchi, Lucia ^b   Paoletti, Francesco ^b   Pancrazzi, Alessandro ^b   Torre, Eugenio ^b   Nishikawa, Mitsuo ^b   Zingariello, Maria ^b   Di Baldassarre, Angela ^b   Rana, Rosa Alba ^b   Lorenzini, Rodolfo ^b   Alfani, Elena ^b   Migliaccio, Giovanni ^b   Migliaccio, Anna Rita ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOPOIETIN; TRANSCRIPTION FACTOR GATA 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL TRANSPORT; CONTROLLED STUDY; EXTRACELLULAR FLUID; FIBROSIS; HEMATOPOIESIS; MEGAKARYOCYTE; MOUSE; MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; STEM CELL; THROMBOCYTOPOIESIS;

EID: 20944437340     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1320     Document Type: Article

References (40)

1. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
3. Hoffman R. Agnogenic myeloid metaplasia. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. Hematology: Basic principles and practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:1172-1188.
4. Yan XQ, Lacey D Fletcher C, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 1995;86:4025-4033.
5. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402-409.
6. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia: French Society of Bone Marrow Transplantation. Br J Haematol. 1997;98:1004-1009.
7. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255-2258.
8. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
9. Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. Prog Clin Biol Res. 1984;154:427-454.
10. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86:419-431.
11. Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells. 2001;19:397-407.
12. Orkin SH. Transcription factors that regulate lineage decisions. In: Stamatoyannopoulous G, ed. The Molecular Basis of Blood Diseases. Philadelphia PA: WB Saunders; 2000:80-120.
13. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399-406.
14. Shivdasani RA, Fujiwara Y, McDevitt MA, et al. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. Embo J. 1997;16:3965-3973.
15. Zhou W, Toombs CF, Zou T, et al. Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment. Blood. 1997;89:1551-1559.
16. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369-4383.
17. Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol. 1997;99:739-745.
18. Vyas P, Ault K, Jackson CW, et al. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93:2867-2875.
19. McDevitt MA, Shivdasani RA, Fujiwara Y, et al. A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A. 1997;94:6781-6785.
20. low mice). Blood. 2001;97:3040-3050.
21. low mice). Blood. 2002;100:1123-1132.
22. low mice. Prepublished on August 3, 2004, as DOI 10.1182/blood-2004-01-0193. (Now available as Blood. 2004;104:3573-3580).
23. low mice. Prepublished on August 3, 2004, as DOI 10.1182/blood-2004-01-0193. (Now available as Blood. 2004;104:3573-3580).
24. th ed. New York, NY: Churchill Livingstone; 2003:267-288.
25. Zon LI, Youssoufian H, Mather C, et al. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci U S A. 1991;88:10638-10641.
26. De Maria R, Zeuner A, Eramo A, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature. 1999;401:489-493.
27. Migliaccio AR, Rana RA, Sanchez M, et al. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1 low mouse mutant. J Exp Med. 2003;197:281-296.
28. Williams N, Eger RR, Jackson HM, et al. Two-factor requirement for murine megakaryocyte colony formation. J Cell Physiol. 1982;110:101-104.
29. Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002;99:381-383.
30. Chagraoui H, Komura E, Tulliez M, et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-3503.
31. Sambrook J, Fritsch, EF, Maniatis, T. Molecular cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
32. Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 1996;87:5006-5015.
33. Schmitt A, Jouault H, Guichard J, et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000;96:1342-1347.
34. Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood. 1990;75:1540-1548.
35. Le Bousse-Kerdilès MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88:4534-4546.
36. Grass JA, Boyer ME, Pal S, et al. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA. 2003;100:8811-8816.
37. Vyas P, McDevitt MA, Cantor AB, et al. Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene. Development. 1999;126:2799-2811.
38. Papayannopoulou T. Bone marrow homing: the players, the playfield, and their evolving roles. Curr Opin Hematol. 2003;10:214-219.
39. Vannucchi A, Bianchi, L, Pancrazzi, A, et al. Reduced GATA-1 content in megakaryocytes of patients with idiopathic myelofibrosis [abstract]. Blood. 2004;102:2457.
40. Thiele J, Lorenzen J, Manich B, et al. Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis. Acta Haematol. 1997;97:137-143.